Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab
Of patients with initial SD, 40% developed a subsequent objective response with improved long-term prognosis comparable to patients with initial response. More than 20% exhibited continued disease control.
Authors
- Kasper Madsen (ORCID: https://orcid.org/0009-0006-7612-3906)
- Marco Donia (ORCID: https://orcid.org/0000-0003-4966-9752)
- Eva Ellebæk (ORCID: https://orcid.org/0000-0001-6748-9232)
- Inge Mansfield Noringriis (ORCID: https://orcid.org/0000-0001-7802-2099)
- Charlotte Aaquist Haslund (ORCID: https://orcid.org/0009-0004-6571-2196)
- Inge Marie Svane (ORCID: https://orcid.org/0000-0002-9451-6037)
- Lars Bastholt (ORCID: https://orcid.org/0000-0001-5478-9826)
- Henrik Schmidt (ORCID: https://orcid.org/0000-0002-4063-3561)
Institutions
- Aalborg University Hospital (DK)
- Odense University Hospital (DK)
- Herlev Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1038/s41416-025-03048-8
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- Bristol-Myers Squibb
- AstraZeneca
- Les Laboratories Pierre Fabre
- Novo Nordisk
- Genentech